Gestational Weight Gain and Pregnancy Outcomes After GLP-1 Receptor Agonist Discontinuation
Top Cited Papers
- 23 December 2025
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 334 (24) , 2186-2196
Abstract
Importance: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are contraindicated in pregnancy. Discontinuation of GLP-1RAs proximal to pregnancy could affect gestational weight gain and pregnancy outcomes. Objective: To compare gestational weight gain and pregnancy outcomes with and without exposure to GLP-1RAs before or during early pregnancy. Design, Setting, and Participants: Retrospective cohort study of 149 790 singleton pregnancies delivered between June 1, 2016, and March 31, 2025, within a single academic health system. Exposure: A GLP-1RA order between 3 years before and 90 days after conception, with propensity score matching of each exposed pregnancy to 3 unexposed pregnancies. Main Outcomes and Measures: The primary outcome was gestational weight gain. Secondary outcomes were excess gestational weight gain, large and small for gestational age birth weight, birth weight percentile for gestational age and sex, birth length, preterm delivery, cesarean delivery, gestational diabetes, and hypertensive disorders of pregnancy. Results: Among 149 790 pregnancies during the study period, 1792 (448 exposed and 1344 unexposed) were matched for the primary analysis. Exposed pregnancies had mean maternal age of 34.0 years (SD, 4.7 years) and prepregnancy body mass index of 36.1 (SD, 6.5; calculated as weight in kilograms divided by height in meters squared); 378 of 448 (84%) had obesity and 104 of 448 (23%) had preexisting diabetes; 136 (30%) were Hispanic, 49 (11%) were non-Hispanic Black, and 223 (50%) were non-Hispanic White; and 43 (10%) had public insurance. The GLP-1RA–exposed pregnancies had greater gestational weight gain (mean, 13.7 kg [SD, 9.2]) than propensity score–matched unexposed pregnancies (mean, 10.5 kg [SD, 8.0]), a difference of 3.3 kg (95% CI, 2.3-4.2; P < .001). The GLP-1RA–exposed group had a higher risk of excess gestational weight gain (65% vs 49%; risk ratio [RR], 1.32; 95% CI, 1.19-1.47), greater mean birth weight percentile (58.4% vs 54.8%; difference, 3.6%; 95% CI, 0.2%-6.9%), and higher risk of preterm delivery (17% vs 13%; RR, 1.34; 95% CI, 1.06-1.69), gestational diabetes (20% vs 15%; RR, 1.30; 95% CI, 1.01-1.68), and hypertensive disorders of pregnancy (46% vs 36%; RR, 1.29; 95% CI, 1.12-1.49). There was no difference in birth length, risk of large or small for gestational age birth weight, or cesarean delivery. Conclusions and Relevance: In a cohort composed primarily of women with obesity, GLP-1RA use with subsequent prepregnancy or early pregnancy discontinuation was associated with more gestational weight gain and a higher risk of preterm delivery, gestational diabetes, and hypertensive disorders of pregnancy.Keywords
This publication has 33 references indexed in Scilit:
- Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonist Use During the First Trimester in Pregnant Women With Type 2 DiabetesThe American Journal of Cardiology, 2025
- Preconception glucagon-like peptide-1 receptor agonist use associated with decreased risk of adverse obstetrical outcomesAmerican Journal of Obstetrics and Gynecology, 2025
- Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early PregnancyJAMA Internal Medicine, 2024
- Trends in delivery hospitalizations with pregestational and gestational diabetes mellitus and associated outcomes: 2000–2019American Journal of Obstetrics and Gynecology, 2022
- Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the USJAMA Health Forum, 2021
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or ObesityJAMA, 2021
- Gestational Weight Gain: Update on Outcomes and InterventionsCurrent Diabetes Reports, 2020
- Greater early and mid‐pregnancy gestational weight gains are associated with excess adiposity in mid‐childhoodObesity, 2016
- Multiple imputation using chained equations: Issues and guidance for practiceStatistics in Medicine, 2010
- Does Gestational Weight Gain Affect the Risk of Adverse Maternal and Infant Outcomes in Overweight Women?Maternal and Child Health Journal, 2008